President Donald Trump's introduction of a Pfizer executive at the White House Wednesday was met with a roar of boos from the ...
Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...
Pfizer (NYSE:PFE) has decided to end R&D and marketing activities related to Beqvez, a one-time gene therapy the company has ...
Pfizer (PFE) will end global development and commercialization of Beqvez, a gene therapy for hemophilia, Nikkei learned Thursday, after the ...
Pfizer will end global development of its bleeding disorder gene therapy, Beqvez, the Nikkei reported on Thursday.
Challenging powerhouse Pfizer, BridgeBio's launch of Attruby is off to a 'great start,' analyst says
An intriguing battle is brewing in the market to treat patients with transthyretin amyloid cardiomyopathy (ATTR-CM). | BridgeBio reported that 1,028 unique prescriptions have been written by 516 ...
Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...
Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...
New DTC platforms like LillyDirect and PfizerForAll are triggering a paradigm shift in how pharma companies connect with ...
Pfizer (NYSE: PFE) has been around for 175 years, but the company's revenue soared to its highest ever only in more recent ...
Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...
Medicare changes will cut $1 billion from 2025 revenue, with Pfizer now responsible for 20% of catastrophic drug costs. Read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results